Tandem Diabetes Care (TNDM) Profit After Tax Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Profit After Tax Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -12.28% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 99.26% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 4.70% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -27.13% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 125.69% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 89.28% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 51.30% |
| 10 | Tandem Diabetes Care | 1.13 Bn | 557.61 Mn | 136.79 Mn | 84.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.38% |
| Dec 31, 2025 | -178.01% |
| Sep 30, 2025 | 8.97% |
| Jun 30, 2025 | -70.05% |
| Mar 31, 2025 | -205.64% |
| Dec 31, 2024 | 102.52% |
| Sep 30, 2024 | 29.46% |
| Jun 30, 2024 | 13.87% |
| Mar 31, 2024 | 65.52% |
| Dec 31, 2023 | -89.26% |
| Sep 30, 2023 | 32.69% |
| Jun 30, 2023 | -137.61% |
| Mar 31, 2023 | -741.81% |
| Dec 31, 2022 | -246.67% |
| Sep 30, 2022 | -945.18% |
| Jun 30, 2022 | -475.65% |
| Mar 31, 2022 | -191.73% |
| Dec 31, 2021 | -36.42% |
| Sep 30, 2021 | 161.59% |
| Jun 30, 2021 | 114.79% |